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Neural changes associated with appetite information
processing in schizophrenic patients after 16 weeks of
olanzapine treatment
E Stip1,2, OV Lungu1,3,4, K Anselmo1,2, G Letourneau1,2, A Mendrek1,2, B Stip5, O Lipp1,3, P Lalonde1,2 and LA Bentaleb1,2
There is evidence that some atypical antipsychotics, including olanzapine, can produce unwanted metabolic side effects, weight
gain and diabetes. However, neuronal correlates of change related to food information processing have not been investigated
with these medications. We studied the effect of a pharmacological manipulation with an antipsychotic known to cause weight
gain on metabolites, cognitive tasks and neural correlates related to food regulation. We used functional magnetic resonance
imaging in conjunction with a task requiring visual processing of appetitive stimuli in schizophrenic patients and healthy
controls before and after 16 weeks of antipsychotic medication with olanzapine. In patients, the psychological and neuronal
changes associated following the treatment correlated with appetite control measures and metabolite levels in fasting blood
samples. After 16 weeks of olanzapine treatment, the patients gained weight, increased their waist circumference, had fewer
positive schizophrenia symptoms, a reduced ghrelin plasma concentration and an increased concentration of triglycerides,
insulin and leptin. In premotor area, somatosensory cortices as well as bilaterally in the fusiform gyri, the olanzapine treatment
increased the neural activity related to appetitive information in schizophrenic patients to similar levels relative to healthy
individuals. However, a higher increase in sensitivity to appetitive stimuli after the treatment was observed in insular cortices,
amygdala and cerebellum in schizophrenic patients as compared with healthy controls. Furthermore, these changes in neuronal
activity correlated with changes in some metabolites and cognitive measurements related to appetite regulation.
Translational Psychiatry (2012) 2, e128; doi:10.1038/tp.2012.53; published online 19 June 2012
Introduction
There is increasing evidence that some atypical antipsycho-
tics, including olanzapine, can produce metabolic side effects.
In a recent review, De Hert et al.1 concluded that ‘although
some drug receptor-binding affinities correlate with specific
cardiovascular and metabolic abnormalities, the exact phar-
macological mechanisms underlying these associations
remain unclear’. In fact, a recent meta-analysis confirmed
that olanzapine treatment resulted in more weight gain,
cholesterol and glucose elevation than all other second-
generation antipsychotics, except for clozapine.2 For
instance, it has been shown that olanzapine produced
statistically more weight gain than risperidone (mean differ-
ence: 2.44 kg), aripiprazole and ziprasidone (mean difference:
3.9 and 3.82 kg, respectively). Naturalistic and controlled
clinical trials3–7 suggest that one of the ways olanzapine can
lead to changes in the patterns of food intake is by increasing
appetite8–12 preference for certain diet.13,14
Moreover, it has been suggested that antipsychotics in
general can contribute to decreased caloric dissipation via
diminished physical activity,6 due to their sedative effects.15
However, Gothelf and co-workers13 prospectively measured
body mass indices, caloric intake and energy expenditure in
10 olanzapine-treated subjects and in a matched group of
patients treated with haloperidol, and found that at 4-week
follow-up, patients had increases in both caloric intake and
body mass index, without any change in their resting and daily
energy expenditure. Thus, caloric intake seems to play an
important role in olanzapine-induced weight gain. Indeed, one
study found that 22.2% of the female patients and 6.4% of the
males fulfilled the criteria for binge eating disorder when both
clozapine and olanzapine were taken together.16
As this brief survey of the literature illustrates, long-term
treatment with olanzapine in schizophrenic patients could lead
to significant weight gain and its associated health problems,
such as diabetes and heart disease. With the increased
prevalence of metabolic illness in schizophrenia, it is of great
clinical importance to determine to what extent the olanzapine
induces changes that reflect trait and state eating behaviors.
The deleterious effects of olanzapine on serum lipids can be
independent of the body mass index or, in addition, to weight-
related effects.17 Albaugh et al.18 recently proposed an
interesting mechanism to explain why olanzapine might cause
metabolic side effects leading to obesity and diabetes based
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on an animal model in male Sprague–Dawley rats. They found
a tendency for increased 14C-2-deoxyglucose uptake into fat
depots of fed rats and a free fatty acid uptake into fat depots
elevation, in parallel with increased adipose tissue lipogen-
esis. These results, consistent with the olanzapine-induced
hyperglycemia hypothesis, suggest that this drug exerts direct
metabolic effects that together favor increased accumulation
of fuel into adipose tissue, yet they do not explain completely
the complexity of the side effects found in humans, such as
the cognitive aspect relative to food intake or the change in
eating behavior in psychotic patients treated with olanzapine.
To date, the associations between behavioral phenotypes and
genetic variability in psychotropic medication responses,
including the effects on obesity, are still unknown. For
instance, both the motivational salience to eat and the factors
involved in eating termination as a function of the hedonic
value of food are all insufficiently investigated. However, there
is increasing evidence19–21 to suggest that there are links
between obesity, perception of appetitive cues, food intake
and reward, which are mediated by specific changes in the
brain activity. Thus, it may be the case that such cognitive
processes may account, at least in part, for the individual
variability in changes of food intake and body weight
associated with antipsychotic treatment in schizophrenia.
In a previous study, we showed that metabolic and cognitive
correlates of dysregulated appetite in schizophrenia may be
related to common neural substrates.22 However, in that
study, patients were prescribed several different antipsychotic
medications. This study was designed to examine changes in
the brain activity associated with 16 weeks of olanzapine
treatment in schizophrenic patients. Thus, the studied
population in this study is pharmacologically homogeneous.
In addition, we were interested to conduct exploratory
analyses that reveal the correlations between psychological
and neuronal changes and appetite control measures and
metabolite levels in fasting blood samples.
Materials and methods
Participants. A cohort of 24 consecutive outpatients (19
men and 5 women) suffering from schizophrenia according to
the DSM-IV criteria, who were not previously exposed to
olanzapine and who were placed under olanzapine treatment
by their psychiatrist, were initially recruited for participation in
this study (Table 1). All patients, with the exception of three
who were under no medication, switched from other
antipsychotics to olanzapine as a result of an insufficient
clinical response. The switch was done without a washout
period as follows: 12 from risperidone, 6 quetiapine, 2
haloperidol, 1 clozapine and 1 perphenazine. The study was
reviewed and approved by the Institutional Review Board of
Centre de Recherche Fernand Seguin and by the Research
Ethics Committee of the Centre de Recherche of the Institut
Universitaire de Ge´riatrie de Montre´al, and all the
participants gave their voluntary and informed consent.
There was no subject with a diabetes mellitus or with
abnormal glucose level at baseline.
During the trial, dosing of olanzapine was flexible depend-
ing of the clinical status of the patients with a daily mean
dosage of 16.18 mg (s.d. 6.97). However, of all 24 patients
recruited initially, only 15 completed both the 16 weeks of
olanzapine treatment and the second scanning session. The
other 9 patients either interrupted their treatment (2 partici-
pants) or did not wish to participate in the second imaging
session (7 participants). Thus, only data from these 15
patients are reported here. In addition, 11 healthy individuals
were scanned only once using the same experimental
protocol and served as controls. Only the data from 10 of
them was used in the study as one healthy individual
displayed unusually large ventricles, thus posing a challenge
for the anatomical standardization of his brain images. Table 1
summarizes the demographic characteristics of all partici-
pants, both patients and controls.
Task description and experimental design. All partici-
pants, healthy controls and patients with schizophrenia alike,
underwent whole-brain functional magnetic resonance
imaging (fMRI) at high field (3 Tesla). Each participant was
in a controlled satiated state. In each fMRI session, subjects
participated in a passive viewing task during two experi-
mental conditions: Appetizing (AC) and Neutral (NC). In all,
10 blocks of 11 pictures each were presented in total, with 5
blocks in the NC condition (emotionally neutral pictures such
as a tourist, rocks, and so on) and 5 blocks in AC condition
(images of food pictures: cakes, pizza, and so on). The two
categories of pictures were selected from the IAPS
(International Affective Picture System)23 and were
matched as much as possible in terms of visual complexity,
while being rated for their appetizing appeal. The selection of
the images was carried out as follows: (a) appetite-related
and appetite-unrelated images were selected from the IAPS
database by the experimenters; these images had similar
valence and intensity ratings, based on the normative data
from the IAPS database; (b) the selected images were
Table 1 Demographic characteristics of schizophrenic (SZ) patients and healthy controls
Healthy controls who
participated in the study
All SZ recruited initially
in the study
All SZ who followed the treatment
and completed the 2 scanning sessions
Total number 10 24 15
Females/males 2/8 5/19 4/11
Age (years; m±s.d.) 33.9 (10.76) 30.04 (9.41) 35.83 (10.12)
Race/ethnicity 100% Caucasians 91.66% Caucasians vs
8.33% Caribbean
86.66% Caucasians
vs 13.33% Caribbean
Note: One healthy control (male, 34 years old) was excluded from the study (his demographic data are not presented in this table) because of unusually large
ventricles, which posed problems for the standardization of the anatomical data.
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mixed-up and then subsequently given to a group of healthy
controls and schizophrenic patients (other than the ones
involved in this study) who classified the images into
appetite-related and appetite-unrelated (neutral); (c) only
the images who were similarly classified by both the
experimenters and these participants and which had similar
valence and intensity based on the IAPS normative ratings
were included in the study.
Each block lasted for 31.68 s and was separated from
others by resting periods of 14.4 s, during which subjects
watched a cyan screen. This passive viewing task was used to
avoid recruiting other cognitive processes in conjunction with
the presentation of the stimuli. Given that appetite is a state
that may last for some time after food stimuli are presented,
the neutral images were always presented before the
appetitive ones (Figure 1a), ensuring that appetite was not
provoked during the NC condition. The subjective responses
to food images were assessed at the end by asking subjects to
rate the average intensity of the appetite felt during the
session, on a visual analog rating scale ranging from 0 (not
appetizing at all) to 5 (biggest appetite ever had in one’s
lifetime). For patients, the first magnetic resonance examina-
tion was scheduled during the first week of the study, before
taking olanzapine medication, and was repeated at the end of
the follow-up, at week 16. All the participants were scanned
approximately at the same time during both scans as hunger
level and appetite changes over time of day.
Clinical assessment and physiological measures. Bio-
metrical data, such as body weight, body mass index,
abdominal circumference and blood pressure, were collected
at weeks 1, 2 and 16. At the same times, blood samples were
taken, and analyzed for fasting glucose, insulin, prolactin,
leptin, ghrelin and lipid profiles. Clinical follow-up also took
place at weeks 1, 2, 8, 12 and 16. Each time, patients were
assessed using the Positive and Negative Symptoms
Scale24 and Calgary Depression Scale for Schizophrenia25
by a single trained physician. Patients completed the Three-
Factor Eating Questionnaire (TFEQ)26 at weeks 1 and 16 to
assess changes in their appetite and eating-related behavior.
The same procedure, but no treatment, was employed for the
group of healthy individuals (control group). In these
participants, the eating habits were assessed with the TFEQ
and their weight and body size were measured. The blood
samples were indeed collected after an overnight fast. The 3 h
was used as a standard period of time for all participants
elapsed between the last meal and the imaging session.
Analysis of psychological and physiological data. The
changes in psychological and physiological variables from
baseline to 16 weeks after treatment pertaining to patients
were analyzed using Wilcoxon’s rank-sum test, a non-
parametric version of the paired sample t-test, which does
not make any assumption regarding the normal distribution of
the data. Given that we had a priori hypotheses about the
direction in which these variable would change (for example,
an increase in weight), we used one-tail significance
threshold Po0.05. The correlations between psychological,
physiological and neuroimaging data were performed using
both Pearson’s correlation coefficient and Spearman’s rank
correlation coefficient (which is less sensitive to outlier
values), and only when the two coefficients agreed did we
reporte the correlation as being significant.
Imaging parameters. A 3 Tesla whole body MR system
(Magnetom Trio, Siemens Medical Systems, Erlangen,
Germany) was used for image acquisition. In each fMRI
session, structural images were acquired in sagittal plane by
using an MPRAGE (magnetization-prepared rapid acqui-
sition) imaging sequence (176 slices, TR¼ 13 ms; TE¼
4.92 ms; FA¼ 251; FoV¼ 256 mm2; matrix size¼ 256 256;
slice thickness¼ 1 mm, voxel size¼ 1 mm3). Whole brain
fMRI was performed using an echo-planar imaging sequence
measuring blood oxygenation level-dependent (BOLD) signal
(TR¼ 3000 ms; TE¼ 30 ms; FA¼ 901; FoV¼ 224 mm2;
matrix size¼ 64 64; slice thickness¼ 3.5 mm, voxel
size¼ 3.5 mm3; 41 slices, 160 volumes). Functional slices
were oriented in transverse plane and were angled to be
parallel to the AC–PC line. An inline retrospective motion
correction algorithm was employed while the echo-planar
imaging images were acquired.
Figure 1 Patients were scanned before and after 16 weeks of olanzapine treatment. In each functional magnetic resonance imaging (fMRI) session, given that appetite is
a state that may last for some time after food stimuli are presented, the blocks of appetitive stimuli were always presented last to prevent the appetite to develop during the
presentation of the neutral stimuli. In each block, there were 11 neutral or appetite-related pictures (depending on the block type) presented.
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Preprocessing of imaging data. The Brain Voyager QX
(Brain Innovation B.V., Maastricht, The Netherlands) software
was used for fMRI data preprocessing and analysis. The
functional bi-dimensional images were preprocessed to
correct for the difference in time slice acquisition. In addition
to linear de-trending, a high-pass filter of three cycles per time
course (frequency domain) was applied to the corrected two-
dimensional slices. Thereafter, the functional series was
preprocessed to correct for possible motion artifacts and to
ensure that movements in any direction did not exceed 3 mm.
These images were subsequently used to reconstruct the
three-dimensional functional volume for each subject and run.
The three-dimensional functional volume was aligned with the
corresponding anatomical volume, and both were normalized
to standard Talairach space.27 Spatial smoothing using a
Gaussian kernel at 8 mm full-width at half-maximum was
applied to the three-dimensional functional data.
Analysis of imaging data. A blocked-design approach was
employed for data analysis. For each scanning session, we
defined two predictors (Appetitive and Neutral), corresponding
to the blocks of presentation of appetitive and neutral images.
These predictors were first entered as fixed factors in a single
subject general linear model, and then the parameters of this
general linear model were subsequently entered into a second
level of analysis corresponding to a random-effect general
linear model that was used for group analysis.28 The criteria
used to display the activation maps were a cluster size of 108
adjacent significant voxels (corresponding to a volume of
108 mm3 or four functional voxels of 3 3 3 mm3 each) and a
statistical threshold for each voxel in the cluster of Po0.005
(uncorrected), which in turn corresponds to Po0.05 family-wise
error for a maximum number of 10 clusters of activation
surpassing this 0.005 threshold.
We were interested in one interaction contrast in our main
analysis: the difference between sessions (Session 24Ses-
sion 1) in schizophrenic patients regarding the difference
between the two types of stimuli (AC4 and NC). This contrast
(assessed in each voxel using a one-sample t-test for the
variable describing the difference (AppetitiveSession 2
NeutralSession 2)(AppetitiveSession 1NeutralSession 1)) identi-
fied the brain regions, which became more or less sensitive to
appetitive stimuli as a result of olanzapine treatment. In addition,
the activated clusters obtained as a result of this contrast were
defined as regions of interest (ROIs) and further analyses were
performed separately for each of them by taking into account the
estimation of the BOLD signal change averaged over all voxels
in the ROI and using the SPSS software (SPSS, Chicago, IL,
USA). Specifically, we performed correlation between the
changes in the brain activity in these ROIs and various
psycho-physiological measures (for example, TFEQ or Positive
and Negative Symptoms Scale scores, concentration of
metabolites, and so on). In addition, we estimated the values
of the BOLD signal change in these ROIs for the control subjects
to identify in which of them the neuronal activity was: (a)
perturbed before the treatment (relative to controls) and brought
back to ‘normal’ by the treatment or (b) at ‘normal’ levels before
the treatment and then perturbed as a result of the clinical
intervention. We also performed a secondary analysis, similar to
that in our previous paper,22 where we compared the brain
activity specific to appetitive stimuli among patients after the
treatment with that of healthy controls. Whereas previously we
compared healthy controls and schizophrenic patients under
various antipsychotic medications (except olanzapine), here we
assessed these group differences after patients were all under
the influence of the same antipsychotic, namely olanzapine.
Results
Physiological changes following olanzapine treatment.
At the end of 16 weeks of olanzapine treatment, 73% of the
patients (11/15) gained between 2 and 7 kg in weight, a
Table 2 Changes in SZ patients before and after the treatment
SZ before treatment (m±s.d.) SZ after treatment (m±s.d.) One-tailed
P-value
Weight (kg) 82.00±16.76 83.52±15.93 0.03
TFEQ
Factor 1 8.60±3.83 8.40±3.83 0.32
Factor 2 5.46±2.69 5.46±2.85 0.27
Factor 3 4.06±2.84 4.13±3.04 0.27
PANSS, positive 20.80±5.79 18.53±4.95 0.03
PANSS, negative 18.06±4.21 18.53±5.05 0.47
PANSS, general 39.26±9.36 36.53±10.93 0.16
PANSS, total 78.13±15.05 73.60±18.93 0.19
Glucose (mmol l1) 4.90±0.49 5.05±1.02 0.07
Cholesterol (mmol l1) 4.31±1.09 4.45±0.54 0.21
Triglyceride (mmol l1) 1.10±0.74 1.37±0.88 0.03
HDL (mmol l1) 1.16±0.24 1.17±0.34 0.47
LDL (mmol l1) 2.65±0.97 2.65±0.54 0.41
Chol LDL 3.98±1.62 4.00±1.22 0.28
Insulin (pmol l1) 45.06±30.45 74.76±49.72 0.008
Prolactin (mg l1) 27.98±51.13 16.12±10.33 0.45
Leptin (ng ml1) 9.17±14.08 11.71±12.9 0.02
Ghrelin (pg ml1) 1062.46±379.33 989.09±380.85 0.04
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; PANSS, Positive and Negative Symptoms Scale; SZ, schizophrenic; TFEQ, Three-Factor
Eating Questionnaire.
Bold indicates significant differences pre- to post-treatment (Po0.05, one-tailed), measured with Wilcoxon’s signed-rank test.
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change that was statistically significant (Table 2). The
treatment also significantly reduced Positive and Negative
Symptoms Scale positive symptoms and the plasma
concentration of ghrelin, while increasing the concentration
levels of triglycerides, insulin and leptin hormones.
Change in brain activity related to cognitive processing
of food stimuli after olanzapine treatment. The difference
in the brain activity between AC and NC was elevated in
patients in eight brain areas, as a result of olanzapine
treatment (Table 3 and Figure 2). No other brain region
displayed the opposite pattern of activity: a decrease in the
difference between the two experimental conditions from
Session 1 to Session 2. These eight regions were located
in right premotor area, fusiform (2 ROIs) and left
parahippocampal (amygdala) and postcentral gyri
(somatosensory cortex), as well as in right insula (2 ROIs)
and semi-lunar cerebellar lobule. The detailed ROI analysis
revealed that in four of these regions (right premotor area,
both right and left fusiform gyri and the left somatosensory
cortex), olanzapine treatment brought the BOLD signal in
response to appetitive stimuli in schizophrenic patients back
to levels comparable with those seen in healthy controls
(Figure 3a).
In the remaining regions, in both insular ROIs
(F(2,37)¼ 5.72, Po0.01 and F(2,37)¼ 4.00, Po0.03), amyg-
dala (F(2,37)¼ 2.98, Po0.05) and cerebellum
(F(2,37)¼ 4.66, Po0.02), the effect of the treatment was an
‘overshoot’ in the BOLD signal in response to appetitive
images, significantly above levels seen in healthy controls
(Figure 3b).
Correlations between physiological measurements and
appetite regulation (TFEQ) as a result of olanzapine
treatment. We observed significant negative correlations
between the difference pre- and post-treatment measured for
Factor 1 of the TFEQ (dietary restraint) and the same
difference measured for the levels of cholesterol (r¼0.664;
Po0.05, N¼ 15), low-density lipoprotein (LDL) (r¼0.661;
Po0.05, N¼ 15), chol/low-density lipoprotein (r¼0.573;
Po0.05, N¼ 15) and leptin (r¼0.496; Po0.05, N¼ 15).
These correlations indicate that the higher the score
difference in dietary restraint as a result of the treatment,
the lower the difference in concentration of these metabolites
and hormones in the fasting blood. For the differences pre- to
post-treatment for Factors 2 (disinhibition) and 3 (hunger) of
the TFEQ, we observed only positive correlations with ghrelin
concentration after the treatment (r¼ þ 0.530; Po0.05,
N¼ 15) and difference pre- to post-treatment in chol/LDL
(r¼ þ0.571; Po0.05, N¼ 15) blood concentrations,
respectively. These show that after the treatment increased
levels in ghrelin concentration are associated with poor
Table 3 Brain regions in which the difference in BOLD signal between appetitive and neutral condition increased significantly among patients as a result of olanzapine
treatment
Contrasts and regions Talairach coordinates Volume (mm3) Maximum t
AC4NC (patients: post-4pre-treatment) t (29)
Right SMA (BA6) 56 3 35 565 3.52
Right fusiform gyrus (BA37) 44 62 10 2253 3.97
Right posterior insular cortex (BA13) 41 10 13 146 3.56
Right fusiform gyrus (BA37) 36 39 13 320 3.47
Right posterior insular cortex (BA13) 35 17 16 178 3.40
Left semilunar lobule (cerebellum VIIIA) 7 68 38 133 3.31
Left PHG/amygdala (BA35) 26 5 12 330 3.46
Left postcentral gyrus (BA3) 58 16 31 240 3.35
Abbreviations: AC, appetitive condition; BA, Brodmann area; BOLD, blood oxygenation level dependent; NC, neutral condition; PHG, parahippocampal gyrus; SMA,
supplementary motor area.
Figure 2 Brain regions in which the difference in blood oxygenation level dependent (BOLD) signal between appetitive and neutral condition increased significantly among
patients as a result of olanzapine treatment.
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control of eating behavior when subjects are faced with
appetitive stimuli, whereas higher differences in
concentration of low-density lipoproteins (chol/LDL) are
associated with a high susceptibility to hunger cues. All
these results indicate that the metabolic side effects of
olanzapine treatment are accompanied by cognitive changes
in appetite regulation and control.
Correlations between physiological measurements and
BOLD signal changes as the result of olanzapine
treatment. We found several correlations between
changes in BOLD signal as a result of treatment, indicating
an increase in sensitivity to appetitive information, and
changes in physiological measurement related to
olanzapine treatment. With two exceptions, most of these
correlations were negative. For example, we found that the
difference in neuronal activity pertaining to appetitive stimuli
in premotor area correlated negatively with that of
triglycerides (r¼0.463; Po0.05, N¼ 15), in fusiform
gyrus,with glucose (r¼0.573; Po0.05, N¼ 15) and leptin
(r¼0.519; Po0.05, N¼ 15) concentrations, in insula, with
the changes in triglyceride (r¼0.503; Po0.05, N¼ 15) and
chol/LDL (r¼0.472; Po0.05, N¼ 15) concentrations, and in
amygdala, with changes in the levels of glucose (r¼0.449;
Po0.05, N¼ 15), insulin (r¼0.544; Po0.05, N¼ 15) and
prolactin (r¼0.456; Po0.05, N¼ 15). Only in the fusiform
gyrus (cluster 4 in Table 3), we found positive correlations
between the BOLD signal and changes in high-density
Figure 3 Changes in blood oxygenation level dependent (BOLD) signal for appetitive and neutral condition in each group (patients pre-treatment, patients post-treatment,
healthy controls) in each region of interest (ROI). (a) Regions in which the BOLD signal for appetitive stimuli was similar in magnitude among patients post-treatment with that
corresponding for healthy controls. (b) Regions in which the BOLD signal for appetitive stimuli was significantly higher in patients after treatment than that among healthy
controls. *Po0.05.
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lipoprotein (r¼ þ0.473; Po0.05, N¼ 15) and ghrelin
concentrations (r¼ þ0.679; Po0.05, N¼ 15). It is
interesting to note that of all regions, the activity in the
fusiform gyrus, whose level is brought back to ‘normal’ after
olanzapine treatment, was the one that correlated with
changes in many metabolites, indicating perturbations of
appetite (that is, positive correlation with ghrelin and negative
correlation with leptin).
Correlations between appetite regulation (TFEQ) and
BOLD signal changes as a result of olanzapine
treatment. The most interesting correlations were those
observed between changes in appetite regulation and those
in BOLD response to appetitive stimuli following olanzapine
treatment. Here we found only positive and significant
correlations between TFEQ Factor 2 (disinhibition) and
changes in BOLD signal in both fusiform gyri (r¼ þ0.498;
Po0.05, N¼ 15 and r¼ þ0.449; Po0.05, N¼ 15) and
amygdala (r¼ þ 0.449; Po0.05, N¼ 15). These corre-
lations indicate that perturbations in appetite regulation,
especially the disinhibition in the face of food-related stimuli,
are associated with an increased neuronal response to these
stimuli in the limbic system.
Brain regions sensitive to appetitive stimuli in
schizophrenic patients under olanzapine relative to
healthy controls. When comparing the group differences
for the contrast AC4NC, we observed a wide network that
was more activated among patients than among healthy
controls (Table 4). This network was not only similar to that
observed in the previous study, where patients were under
various antipsychotic medications, except olanzapine, but
this time, the areas were much larger (for example, bigger
volume at the same threshold), in line with the increase in
appetite dysregulation after the onset of the treatment.
Discussion
In this study, we investigated the physiological, psychological
and neuronal activity changes in schizophrenic patients
following 16 weeks of olanzapine treatment. Even after such
a short time of taking olanzapine, patients presented
important physiological changes, including weight gain, which
correlated with changes in the concentration of some
metabolites. The negative relationship between body weight
and ghrelin plasma concentration found in this study is well
established in the literature on obesity29,30 and lower ghrelin
levels are also found in some eating disorders, such as binge
eating.31 Similarly, increased levels of triglycerides, such as
that found in our results, have been associated in the past with
overeating in rats,32 and with bulimia nervosa and binge
eating in humans.33,34 Although leptin is an appetite-reducing
hormone, higher levels of leptin for longer periods of time may,
in fact, indicate appetite dysfunction due to the development
of resistance to leptin, such as it is the case in obese
individuals.35 In addition, there is a strong association
between higher levels of leptin and insulin resistance in both
normoglycemic individuals36 and type 2 diabetes.37 In
summary, these physiological changes suggest that hormonal
balance involved in appetite regulation may be perturbed in
schizophrenic patients after 16 weeks of olanzapine treat-
ment, suggesting that these individuals may be at risk of
developing metabolic and/or cardiovascular disorders as a
direct consequence of medication.17 In fact, the recommen-
dations outlined by De Hert and co-workers17 to screen and
monitor schizophrenic patients taking atypical antipsychotics
are more important in the light of our results: we were able to
detect these changes even after a relatively short interval of
taking the medication.
We also found activation in the frontal cortex, fusiform
gyrus, amygdala and insula when comparing the brain activity
in response to appetite-related stimuli after the treatment
relative to baseline. It is interesting to note that some of these
latter brain regions are part of the limbic system, typically
involved in the processing of appetite regulation information.
In our experiment, we found hyperactivity in these regions
relative to controls, which is the opposite of what is typically
found in tasks that required cognitive processing of food
images in anorexia nervosa, for example.38 However, these
findings are in concordance with a new perspective of eating
as an automatic behavior39 and the evidence that schizo-
phrenic individuals are more sensitive to external cues,40
which in our case increased after the olanzapine treatment.
The novelty of our findings is that although antipsychotic
treatment brought the activity in fusiform gyrus to levels
comparable with that of healthy individuals, its functional role
in behavioral control of appetite in response to metabolic
perturbations41,42 seems compromised.
Parsing the salient variables in people with mental illness
such as schizophrenia is a crucial need as mortality from
physical health causes is the most common cause of
premature mortality in people with chronic mental illness.43
Table 4 Brain regions in which the difference in BOLD signal between AC and NC is significantly higher among patients than among healthy controls after the
olanzapine treatment
Contrasts and regions Talairach coordinates Volume (mm3) Maximum t
AC4NC (patients4controls) t (23)
Right SMA (BA6)/posterior insula (BA13) 57 1 34 11 110 5.73
Right fusiform gyrus (BA37) 45 61 8 25 418 6.15
Right amygdala/parahippocampal gyrus 18 7 14 1554 4.40
Left paracentral lobule (BA5) 3 34 55 2128 4.20
Left amygdala/parahippocampal gyrus 24 4 11 2391 5.47
Left postcentral gyrus (BA3) 54 16 34 10 865 5.55
Abbreviations: AC, appetitive condition; BA, Brodmann area; BOLD, blood oxygenation level dependent; NC, neutral condition; SMA, supplementary motor area.
The t-value represents the magnitude of the increase in the difference between conditions (AC4NC) from pre- to post-treatment. The t-value represents the
magnitude of the difference between the two groups when considering the difference between conditions (AC4NC).
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Recent molecular examinations have assumed biological
differences in hunger, satiation and satiety mechanisms in
schizophrenia and have focused on metabolic signals.40,44
Here we found that these signals, which were perturbed by
olanzapine treatment, correlated both with changes in
neuronal activity in the fusiform gyrus and limbic system
(amygdala and insula) during the presentation of appetitive
images, as well as with measurements indicating a dysfunc-
tion in cognitive control of appetite.
Examining differences in neural responses to food pictures
between, for instance, obese and lean individuals may help us
understand weight-related differences in responses to ‘real-
life’ external cues, such as food displays. In fMRI studies,
using a block design, Rothemund et al.45 and Stoekel et al.46
assessed responses to images of high calorie foods, and low
and neutral images following abstinence. The obese indivi-
duals showed greater activation to high calorie foods vs
neutral in the insula and caudate/putamen.45,46
These trials suggest that, similar to our sample olanzapine-
treated patients who are more vulnerable to become over-
weight, obesity is associated with abnormal responses to
visual food cues in a distributed network of brain regions that
might be involved in reward/motivation, emotion/memory and,
more recently, to proximal salience.47 Although it is difficult to
infer cognitive functions from brain activation, this could reflect
individuals’ association of food cues with cognitive efforts to
restrain intake.22 The insula is proposed to play a specific role
in a salient network, which, according to Planiyappan and
Liddle,47 could be a mechanism of dysfunctional psychosis. It
is possible that greater reward response in restrainers may be
related to a phenotype that comes with restraint: disinhibition,
that is, the tendency for restraint to break down when
confronted by emotional or external cues to eat.48 In DelParigi
et al.’s49 positron emission topmography study, obese adults
who showed greater post-fast increases in activation to food
tastes in the midbrain and insula also reported higher
disinhibition.
Theoretically, an important candidate mechanism for
olanzapine and other second-generation antipsychotics
(SGA)-induced increases in appetite is the blockade of
receptors such as 5-HT2A, 5-HT2C serotonergic; D1, D2,
D3 and D4 dopaminergic; H1 histaminergic, a1- and a2-
adrenergic and cholinergic50–58 involved in appetite regula-
tion. Some clinical trials implicate the polymorphism of the 5-
HT2C receptor gene in weight gain in response to SGAs.58–61
Wirshing and co-workers53 found a logarithmic relationship
between H1 receptor affinity in patients treated with clozapine
(N1/420), olanzapine (N1/413), risperidone (N1/438), halo-
peridol (N1/443) and sertindole (N1/48), but this is not specific
to SGAs.62 Nevertheless, rank ordering of specific SGAs’
propensities to increase body weight against all their binding
affinities at the human brain receptors argues against
antagonism of a single receptor as a sufficient cause for
SGA-induced weight gain.55,56 For instance, ziprasidone also
binds with substantial affinity to the 5-HT2C and H1
receptors63 Hence, it is possible that simultaneous blockade
of several (rather than single) receptors, for example, H1, 5-
HT2, D2 and acetylcholine receptors, may have a synergistic
effect on increased appetite and food intake.5,64,65 It might be
that the muscarinic receptor M3 is involved as antipsychotics,
which do not produce metabolic side effects, have no affinity
for this receptor. However, what seems more relevant from a
clinical perspective is that changes in dopaminergic brain
pathways induced by long-term treatment with olanzapine are
accompanied by metabolic changes and perturbations in the
behavioral control of appetite, which are similar to those
observed on short term in healthy subjects injected intrave-
nously with ghrelin.42
The majority of antipsychotics have been tested to measure
if they modify the cognitive mechanism of schizophrenia
anomalies. In the obesity or appetite research field, some
studies are attempting to break down the mechanisms
underlying excessive food intake by moving beyond food
intake and food cue paradigms into the domain of cognitive
tasks designed to test impulsive behavior such as the go/no-
go task66 or tasks designed to tap responsiveness to different
types of reward.67 Our study design is a first step in combining
a cognitive paradigm (here implicit) to a food-related informa-
tion processing.
Limitations
Given that the patients are on medication, it is therefore
difficult to draw conclusions on the processes underlying the
performance and activation per se in schizophrenia. This
question can only be answered while examining medication-
naı¨ve patients. Evaluating patients before introducing treat-
ment is one way to dissect the effect of schizophrenia per se
from the impact of treatment. We also did not employ the best
control condition, such as another treatment arm with a weight
neutral antipsychotic drug. One limitation of this study is that
the control group was only scanned once, resulting in noise. It
might be possible that there was a test–retest effect in the
schizophrenic sample (for example, difference in familiarity
with the paradigm). If the controls had been re-scanned as
well, we would have been able to control some of these test–
retest effects. However, given that our participants did not
have to process cognitively the images that were presented,
but only to watch and react to them emotionally, there is
evidence coming from past studies, which suggests that the
emotional response to the same IAPS images tends to be
stable over time.68 In addition, the comparisons of interest are
the changes in physiological, psychological and neuroimaging
variables due to the 16 weeks of treatment, seen in patients.
We thus used the healthy controls just to assess whether the
treatment leads, in patients, to restoration of the brain activity
to levels comparable to that of controls. Also, our current
design might not be sufficient to distinguish nonspecific
changes in responsiveness from specific cognitive changes
related to the appetite-related cognitive processes that they
are interested in. The time patients stay in the MRI set up was
long enough for them and we did not add other paradigms.
Conclusion
The epidemic of obesity is probably related to the multiple
‘obesogenic’ influences in modern environment. However,
despite the unfortunate attraction of fast food restaurants and
large portion sizes, not everyone becomes obese, suggesting
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that individuals such as patients with schizophrenia differ in
their susceptibility to environmental opportunities to eat. This
vulnerability can also be magnified by the medication they
take.
In this study, we documented that schizophrenic patients
undergoing a treatment with olanzapine are likely to gain
weight, augment their abdominal fat matter and increase their
levels of insulin and leptin, while diminishing the ghrelin blood
concentration. Interestingly, these physiological changes
following the olanzapine treatment were paralleled by an
increased level of activity in the limbic system (amygdala,
insula) in patients relative to controls. Moreover, the neuronal
activity in the amygdala and insula in response to appetitive
stimuli correlated with several physiological measurements
related to appetite regulation. The changes in insulin, leptin
and ghrelin concentrations in our study and the increase in
neuronal activity of the amygdala, which is the site typically
integrating homeostatic and extrinsic influences related to
eating behavior, might be consistent with the hypothesis of a
dopaminergic-mediated feeding control. However, this ques-
tion remains open as it is still difficult to determine precisely
why this dopamine mediation would be different with
olanzapine as compared to some of the other antipsychotics,
including the first generation. One possible explanation could
be that this is related to the mechanisms of neurotransmitter
mediation. The only study dealing with this mechanism is by
Albaugh and co-workers,18 who showed in rats that olanza-
pine led to specific metabolic effects that increased the
accumulation of fuel into the adipose tissue. The clinical
significance of our study stems from the fact that, although the
investigated duration of the treatment was relatively short
(about 4 month), it was enough to reveal changes in the brain
activity and in other physiological parameters that reflect
changes in appetite regulation induced by antipsychotic
medication. Our study, while still exploratory, suggests that
olanzapine treatment in humans induced changes in neuronal
activity in specific brain regions, which correlate with levels of
glucose, insulin, prolactin or the cholesterol/LDL ratio. Further
research is needed to parse the pharmacological and
neuronal mechanisms producing the metabolic side effects
during antipsychotic treatment in schizophrenia.
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